Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 ... - News-Medical.Net

  • email Email to a friend
  • print Print version

Did you enjoy this article?

(total 0 votes)
Try our own cheap Booking Service36 times read : Adjust font size: Decrease font Enlarge font
image

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon initiation of a Phase 2 trial ...

Read this article...



Post your comment comment Comments (0 posted)

copyright